查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
次單元疫苗的全球市場(2022年～2028年)
市場調查報告書
商品編碼
1159392

次單元疫苗的全球市場(2022年～2028年)

Subunit Vaccine Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

全球次單元疫苗的市場規模，在預測期間內預計以10.9％大幅度的年複合成長率成長。促進市場成長的主要原因，是疫苗接種的需求增加，與傳統的疫苗比較的安全性提高，次單元疫苗所提供的優點等。同時，次單元疫苗的生產流程相關的課題，妨礙市場成長。

本報告提供全球次單元疫苗市場調查，市場概要，市場趨勢的分析，各產品類型、各生產類型、各免疫應答類型、各疾病、各地區的分析，競爭情形，再加上主要企業的簡介等，全面性資訊。

目錄

第1章 報告概要

第2章 市場概要與見解

  • 調查範圍
  • 分析師的見解與目前市場趨勢

第3章 競爭情形

  • 主要企業分析
    • GE Healthcare Life Sciences
    • GlaxoSmithKline PLC
    • Merck & Co. Inc.
    • Reber Genetics
    • Sanofi S.A.
  • 主要策略分析
  • COVID-19對主要企業的影響

第4章 市場區隔

  • 全球次單元疫苗市場:各產品類型
    • 蛋白質抗原
    • 多糖類抗原
  • 全球次單元疫苗市場:各生產類型
    • 蛋白質變性
    • 基因工程學
  • 全球次單元疫苗市場:各免疫應答類型
    • 呈現抗原細胞(APCS)
    • 細胞性免疫
    • 細胞激素(Th1、Th2免疫應答)
    • 粘膜
    • 其他
  • 全球次單元疫苗市場:各疾病
    • 感染疾病
    • 白喉、破傷風、百日咳(DTP)
    • HPV
    • 麻疹、腮腺炎、德國麻疹(MMR)
    • 其他

第5章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他的亞太地區
  • 其他地區

第6章 企業簡介

  • Algenex S.L.
  • Arbutus Biopharma Corp.
  • Astellas Pharma Inc,
  • Astrazeneca PLC
  • Emergent Biosolutions
  • Indian Immunologicals Ltd.
  • QED Biosciences Inc.
  • Mitsubishi Tanabe
  • Novartis International AG
  • Pfizer, Inc.
  • Roche Holding AG
  • Shenzhen Kangtai Biological Products
  • Takeda Pharmaceuticals Company Ltd.
  • Vical Inc.
  • Virbac
Product Code: OMR2026551

Title:Global Subunit Vaccine Market Size, Share & Trends Analysis Report, by Product Type (Protein Antigen, and Polysaccharide Antigen), by Production Type (Denaturing of Proteins, and Genetic Engineering), by Immune Responses Type (Antigen-Presenting Cells (APCs), Cell-Mediated Immunity, Cytokines, Mucosal, and Others), and by Disease (Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others) Forecast Period (2022-2028).

The global subunit vaccine market is anticipated to grow at a significant CAGR of 10.9% during the forecast period. The factors fueling the growth of the subunit vaccine market include increasing demand for immunization and better safety as compared to traditional vaccines. The benefits offered by subunit vaccines such as long immunity offered and the low-risk rate associated with the subunit vaccines are propelling the market growth. The challenges associated with the production process of subunit vaccines are hindering the growth of the market.

The global subunit vaccine market is segmented based on the product type, production type, immune response type, and disease. Based on the product type, the market is segmented into protein antigen and polysaccharide antigen. Based on the production type, the market is segmented into denaturing of proteins, and genetic engineering. Based on the type of the immune response, the market is segmented into antigen-presenting cells (APCs), cell-mediated immunity, cytokines, mucosal, and others. Based on the disease, the market is sub-segmented into infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, mumps, and rubella (MMR), and others. The above-mentioned segments can be customized as per the requirements. Based on the production type, the global subunit vaccines market is classified into denaturing of proteins and genetic engineering. The denaturing of proteins segment held a considerable market share owing to the easy production process.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is the leading market for subunit vaccines owing to increased technological advancements and R&D.

The major companies serving the global subunit vaccine market include GE Healthcare Life Sciences, GlaxoSmithKline PLC, Merck & Co. Inc., Reber Genetics, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2019, a private biotechnology company, Algenex SL, delivered disruptive technology for recombinant biologics manufacturing and announced that one of its industrial partners has submitted a dossier to the European Medicines Agency (EMA) for a recombinant subunit vaccine manufacturing by using Algenex' proprietary CrisBio® technology. The submission targeted European marketing authorization through the centralized approval system. This was the first vaccine manufactured using Algenex' CrisBio® technology to be submitted for regulatory approval.

Research Methodology

The market study of the global subunit vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Subunit Vaccine Market Research and Analysis by Product Type

2. Global Subunit Vaccine Market Research and Analysis by Production Type

3. Global Subunit Vaccine Market Research and Analysis by Immune Responses Type

4. Global Subunit Vaccine Market Research and Analysis by Disease

The Report Covers:

  • Comprehensive Research Methodology of the global subunit vaccine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global subunit vaccine market.
  • Insights about market determinants that are stimulating the global subunit vaccine market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Subunit Vaccine Market
  • Recovery Scenario of Global Subunit Vaccine Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. GE Healthcare Life Sciences
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. GlaxoSmithKline PLC
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Merck & Co. Inc.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Reber Genetics
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Sanofi S.A.
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

  • 4.1. Global Subunit Vaccine Market by Product Type
    • 4.1.1. Protein Antigen
    • 4.1.2. Polysaccharide Antigen
  • 4.2. Global Subunit Vaccine Market by Production Type
    • 4.2.1. Denaturing of Proteins
    • 4.2.2. Genetic Engineering
  • 4.3. Global Subunit Vaccine Market by Immune Responses Type
    • 4.3.1. Antigen-Presenting Cells (APCS)
    • 4.3.2. Cell-Mediated Immunity
    • 4.3.3. Cytokines (Direct Th1 Or Th2 Immune Responses)
    • 4.3.4. Mucosal
    • 4.3.5. Others
  • 4.4. Global Subunit Vaccine Market by Disease
    • 4.4.1. Infectious Disease
    • 4.4.2. Diphtheria, Tetanus and Pertussis (DTP)
    • 4.4.3. HPV
    • 4.4.4. Measles, Mumps and Rubella (MMR)
    • 4.4.5. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Algenex S.L.
  • 6.2. Arbutus Biopharma Corp.
  • 6.3. Astellas Pharma Inc,
  • 6.4. Astrazeneca PLC
  • 6.5. Emergent Biosolutions
  • 6.6. Indian Immunologicals Ltd.
  • 6.7. QED Biosciences Inc.
  • 6.8. Mitsubishi Tanabe
  • 6.9. Novartis International AG
  • 6.10. Pfizer, Inc.
  • 6.11. Roche Holding AG
  • 6.12. Shenzhen Kangtai Biological Products
  • 6.13. Takeda Pharmaceuticals Company Ltd.
  • 6.14. Vical Inc.
  • 6.15. Virbac

LIST OF TABLES

  • 1. GLOBAL SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL PROTEIN ANTIGENSUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL POLYSACCHARIDE ANTIGEN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCTION TYPE, 2021-2028 ($ MILLION)
  • 5. GLOBAL DENATURING OF PROTEINS OF SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL GENETIC ENGINEERING OF SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY IMMUNE RESPONSES TYPE, 2021-2028 ($ MILLION)
  • 8. GLOBAL ANTIGEN-PRESENTING CELLS (APCS) SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL CELL-MEDIATED IMMUNITY SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL CYTOKINES SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL MUCOSAL SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL OTHERS SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 14. GLOBALSUBUNIT VACCINE FOR INFECTIOUS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL SUBUNIT VACCINE FOR DTP MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL SUBUNIT VACCINE FOR HPV MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. GLOBAL SUBUNIT VACCINE FOR MMR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 18. GLOBAL SUBUNIT VACCINE FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 19. GLOBAL SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. NORTH AMERICAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 22. NORTH AMERICAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCTION TYPE, 2021-2028 ($ MILLION)
  • 23. NORTH AMERICAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY IMMUNE RESPONSES TYPE, 2021-2028 ($ MILLION)
  • 24. NORTH AMERICAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 25. EUROPEAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 26. EUROPEAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 27. EUROPEAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCTION TYPE, 2021-2028 ($ MILLION)
  • 28. EUROPEAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY IMMUNE RESPONSES TYPE, 2021-2028 ($ MILLION)
  • 29. EUROPEAN SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 30. ASIA-PACIFIC SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 31. ASIA-PACIFIC SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 32. ASIA-PACIFIC SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCTION TYPE, 2021-2028 ($ MILLION)
  • 33. ASIA-PACIFIC SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY IMMUNE RESPONSES TYPE, 2021-2028 ($ MILLION)
  • 34. ASIA-PACIFIC SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 35. REST OF THE WORLD SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 36. REST OF THE WORLD SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 37. REST OF THE WORLD SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCTION TYPE, 2021-2028 ($ MILLION)
  • 38. REST OF THE WORLD SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY IMMUNE RESPONSES TYPE, 2021-2028 ($ MILLION)
  • 39. REST OF THE WORLD SUBUNIT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL SUBUNIT VACCINE MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL SUBUNIT VACCINE MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL SUBUNIT VACCINE MARKET, 2022-2028 (%)
  • 4. GLOBAL SUBUNIT VACCINE MARKET SHARE BY PRODUCT TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL PROTEIN ANTIGENSUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL POLYSACCHARIDE ANTIGEN SUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL SUBUNIT VACCINE MARKET SHARE BY PRODUCTION TYPE, 2021 VS 2028 (%)
  • 8. GLOBAL DENATURING OF PROTEINS OF SUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL GENETIC ENGINEERING OF SUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL SUBUNIT VACCINE MARKET SHARE BY IMMUNE RESPONSES TYPE, 2021 VS 2028 (%)
  • 11. GLOBAL ANTIGEN-PRESENTING CELLS (APCS) SUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL CELL-MEDIATED IMMUNITY SUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL CYTOKINES SUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL MUCOSAL SUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL OTHERSSUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL SUBUNIT VACCINE MARKET SHARE BY DISEASE, 2021 VS 2028 (%)
  • 17. GLOBAL SUBUNIT VACCINE FOR INFECTIOUS DISEASEMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL SUBUNIT VACCINE FOR DTP MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL SUBUNIT VACCINE FOR HPV MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. GLOBAL SUBUNIT VACCINE FOR MMR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 21. GLOBAL SUBUNIT VACCINE FOR OTHERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 22. GLOBAL SUBUNIT VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 23. US SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CANADA SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. UK SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. FRANCE SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. GERMANY SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. ITALY SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. SPAIN SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. REST OF EUROPE SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. INDIA SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. CHINA SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. JAPAN SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 34. SOUTH KOREA SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 36. REST OF THE WORLD SUBUNIT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)